Suanfarma Suanfarma

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu

    Find the latest Drugs in Development and Pipeline Prospector News of GENESIS Pharma.

    Client Virtual Booth

    GENESIS PHARMA

    EVENTS

    • Webinars & Exhibitions

    PRESENTATION(s)

    VIDEO(s)

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Contact SupplierContact Supplier
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Send me more info on How To Grow My Bussiness Digitally?
    GENESIS Pharma
    Greece Flag
    Country
    Country
    Greece
    Address
    Address
    GR- 15232, Halandri – Athens
    Telephone
    Telephone
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://www.genesispharma.com/default.aspx?lang=en-GB&page=1
    Linkedin
    Linkedin
    https://www.linkedin.com/company/genesis-pharma/?originalSubdomain=gr
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Full View ScreenFull Screen View
    • Deals
    Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE

    GENESIS Pharma Announces an Exclusive Distribution Agreement With Regeneron Pharmaceuticals to Commercialize cemiplimab in Greece, Cyprus and Malta

    Details:

    Under the agreement, GENESIS will commercialize the approved product of Regeneron, Libtayo (cemiplimab), which is a PD-1 inhibitor. It is used for the treatment of advanced basal cell carcinoma, cutaneous squamous cell carcinoma and non-small cell lung cancer.


    Lead Product(s): Cemiplimab

    Therapeutic Area: Oncology Product Name: Libtayo

    Highest Development Status: ApprovedProduct Type: Large molecule

    Partner/Sponsor/Collaborator: Regeneron Pharmaceuticals

    Deal Size: Undisclosed Upfront Cash: Undisclosed

    Deal Type: Agreement March 01, 2024

    ASK
    US
    PHARMACOMPASS
    Upload
    your Marketing & Sales content
    • Deals
    Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE

    GENESIS Pharma Announces an Exclusive Distribution Agreement with Deciphera Pharmaceuticals to Commercialize RIPRETINIB in 14 EU Markets in Central and ...

    Details:

    Under the terms of the agreement, GENESIS Pharma will exclusively commercialize Qinlock (ripretinib) for the treatment of fourth-line gastrointestinal stromal tumor.


    Lead Product(s): Ripretinib

    Therapeutic Area: Oncology Product Name: Qinlock

    Highest Development Status: ApprovedProduct Type: Small molecule

    Partner/Sponsor/Collaborator: Deciphera Pharmaceuticals

    Deal Size: Undisclosed Upfront Cash: Undisclosed

    Deal Type: Agreement January 12, 2024

    ASK
    US
    PHARMACOMPASS
    Upload
    your Marketing & Sales content
    Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    fermion-oy-2024-05-13

    Access Virtual Booth

    Contact Supplier

    Send me more info on How To Grow My Business Digitally?
    Post Enquiry
    POST ENQUIRY

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search